Everybody wants a BCMA bispecific. And AbbVie just fronted $90 million to get one from a little-known Silicon Valley biotech called Teneobio.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.Free Subscription